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Abstract
Genome-wide association studies have identified many genetic variants associated with complex
traits. However, at only a minority of loci have the molecular mechanisms mediating these
associations been characterized. In parallel, whilst cis-regulatory patterns of gene expression have
been extensively explored, the identification of trans-regulatory effects in humans has attracted
less attention. We demonstrate that the Type 2 diabetes and HDL-cholesterol associated cis-acting
eQTL of the maternally-expressed transcription factor KLF14 acts as a master trans-regulator of
adipose gene expression. Expression levels of genes regulated by this trans-eQTL are highly-
correlated with concurrently-measured metabolic traits, and a subset of the trans-genes harbor
variants directly-associated with metabolic phenotypes. This trans-eQTL network provides a
mechanistic understanding of the effect of the KLF14 locus on metabolic disease risk, providing a
potential model for other complex traits.
Variants near the maternally-expressed transcription factor KLF14 (Kruppel-like factor 14)
are robustly associated with both Type 2 Diabetes (T2D) and HDL-cholesterol levels in
large-scale genome-wide association studies (GWAS)1,2. These studies have implicated a
group of highly-correlated SNPs including rs4731702 and rs972283 ~14kb upstream of
KLF141,2. KLF14 is the regional gene most likely to be mediating these effects since the
same SNPs show adipose-specific, maternally-restricted cis-regulatory associations with
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KLF14 expression levels, a pattern which mirrors the parent-of-origin effects for T2D-
susceptibility at this locus3.
Since transcription factors such as KLF14 typically modulate expression of other genes in
trans, we tested for association between rs4731702 and expression levels of ~24K probes
(16,663 genes) on the Illumina Human HT12 array in subcutaneous adipose tissue biopsies
from a cohort of 776 healthy female twins4. The enrichment of rs4731702 trans-associations
for low p-values (Figure 1, Supplemental Figure 1) suggests that KLF14 is a master-
regulator of gene expression in adipose tissue. The pattern of trans-associations at KLF14
mirrors the GWAS associations (Fig 2, Suppl Fig 2), and conditioning the trans associations
on rs4731702 abolishes the signal at all other SNPs. These findings indicate that the same
set of SNPs (and presumably the same causal variant) underlies the cis-, trans- and
metabolic trait-associations at this locus.
We focused on the ten genes (TPMT, ARSD, SLC7A10, C8orf82, APH1B, PRMT2, NINJ2,
KLF13, GNB1, MYL5) showing genome-wide significant trans (GWST) associations (p <
5×10−8) driven by rs4731702. First, we sought replication of the trans-associations in an
independent set of adipose tissue samples (deCODE Genetics; N= 589)5. As previously
reported3, the deCODE data revealed a strong maternally-specific cis-association between
rs4731702 and KLF14 expression in adipose tissue (p = 1×10−19) (Table1). This cis effect
was not detected in the MuTHER data due to apparent problems with the KLF14 probe
represented on the Illumina HT12 array used for MuTHER (See methods). Seven of the
GWST genes from the MuTHER analysis had a directionally-consistent trans-association
with p-value <0.05 in the deCODE replication set (Table 1), and we were able to show
parent-of-origin effects for the trans-associations consistent with the maternally-specific cis-
effects for KLF14 expression and T2D-risk3. In the deCODE replication data maternally
inherited trans-associations were markedly more significant than general analyses and no
paternally-inherited trans-associations were seen (Table 1).
The trans-effects explain a substantial portion of the genetically-regulated variation in
GWST expression levels. Our heritability estimates of GWST-gene expression levels ranged
from 0.13 to 0.79: the rs4731702 trans-eQTL explained between 3-7.8% of the variance in
expression, corresponding to 6-25% of the heritability (Table 2). Expression levels of the ten
GWST genes are moderately-correlated in adipose tissue, with a mean ∣pairwise rho∣ of 0.29
(stdev = 0.15). SLC7A10 is the only GWST gene down-regulated by the T2D-risk allele
(and hence the only transcript showing anti-correlated expression levels within the GWST
genes). This pattern is consistent with the known ability of the KLF family of transcription
factors to act as both transcription activators and repressors6.
Further support for the hypothesis that the trans-effects are mediated by KLF14 expression
comes from analysis of transcription-factor binding-sites in trans-associated genes using
PSCAN7 with the JASPAR database8. KLF14 itself is not represented in JASPAR, but other
KLF family members have closely related binding sites (and in some cases have been shown
to compete for the same binding site)9, and KLF4 (the only KLF family member in the
JASPAR database) and KLF14 share highly similar DNA binding C-terminal regions10.
Though we found no evidence for enrichment after correction for multiple-testing when
examining the 10 GWST genes alone, inclusion of a larger number of trans-associated genes
(46 with trans p < 10−4 or 121 with trans p < 10−3) revealed strong evidence of enrichment
for KLF4 binding sites. KLF4 was the most over-represented binding site in the former set
(Bonferroni-corrected p = 0.01) and the second most over-represented site in the latter set
(Bonferroni corrected p = 1.3 ×10−7) after EGR1. These data indicate that one feature of the
transcripts showing trans-associations with the KLF14 SNPs is enrichment for KLF binding
sites.
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Having demonstrated that the same set of SNPs influences cis-expression of KLF14, trans-
expression of members of the GWST-gene network, and a variety of metabolic traits
including T2D and HDL-cholesterol, we sought to clarify the causal connections between
these effects, and in particular to establish whether or not the trans-effects were likely to be
mediating the metabolic associations at KLF14. First, we examined the correlations between
trans-gene expression and concurrently-measured metabolic phenotypes. At an array-wide
Bonferroni threshold of p< 1.9×10−6, expression levels of six of the ten GWST genes are
associated with BMI and HDL-cholesterol, five each with triglycerides and fasting insulin
levels, four with HOMA-IR (an index of insulin sensitivity) and two each with fasting
glucose and adiponectin (Table 3). Compared to all genes on the array, this represents an
enrichment for expression/metabolic phenotype associations, with significance ranging from
p = 0.001 to p = 3.3 ×10−5. The strength of these associations is consistent with a causal link
between trans gene expression and metabolic phenotypes, and provides clues to the
biological processes in which these genes may participate.
Next we examined large-scale association data made available by trait-specific GWAS
meta-analysis consortia, focusing on SNPs in the 250kb surrounding each GWST gene. The
rs4731702 T2D risk-allele is associated with higher fasting insulin1, indicating that the
primary effect on diabetes-risk is mediated by decreased peripheral insulin sensitivity.
Accordingly, we focused on a set of insulin-resistance related traits including fasting
insulin11, fasting glucose11, HOMA-IR11, T2D1, lipids (HDL, LDL, triglycerides)2, body fat
distribution (BMI-adjusted WHR)12 and BMI13. In GWAS datasets ranging in size from
22,044-123,865 individuals, we found eight associations in five genes at a study-wide
significance threshold of 1.03 ×10−4 (Table 4). (See methods for threshold determination).
For example, SNPs near APH1B are associated with HDL (rs2729787; p=9.8 ×10−9) and
triglycerides (rs17184382; p=1.5 ×10−5), and SNPs near KLF13 with BMI-adjusted WHR
(rs4779526; p=1.8 ×10−5) and LDL (rs8034505; p=5.8 ×10−5). In addition, SNPs in MSRA
(expression levels of which marginally failed to reach genome-wide significance: trans-
association p=5.1 ×10−8) have been previously associated with waist circumference10, and
are here associated with triglycerides (rs615171; p=7.5 ×10−7). This pattern of association
signals reveals that variation involving GWST-genes has the potential to impact on insulin-
resistance related traits, and thereby supports the notion that a subset of these genes are
directly implicated in mediating the effects of KLF14 variation on disease-susceptibility.
One of the more interesting transcripts revealed by these analyses is SLC7A10, a member of
the solute carrier family that mediates transport of neutral amino acids. Adipose expression
of SLC7A10 is highly heritable (h2=0.79) and is down-regulated by the KLF14 T2D risk-
allele. SLC7A10 expression is strongly-associated with diverse metabolic phenotypes;
negatively correlated with BMI (p = 3×10−48), insulin (p=1.1×10−51), HOMA-IR (p=7
×10−48), glucose (p=6×10−7), and triglycerides (p =1 ×10−34) and positively correlated with
HDL (p=7×10−30) and adiponectin (p= 1 ×10−12) levels (Table 3). The SLC7A10 locus
contains independent (r2=0.03) SNPs associated with HDL (rs8182584; p=3.2×10−7), and
BMI-adjusted WHR (rs7251505; p=3.2×10−6). The former SNP (rs8182584) is weakly
associated to insulin (p=0.002) and BMI (p =1.4 ×10−3) suggesting that this gene has a
wide-ranging role in metabolism.
Our data provide convincing evidence of a bona fide adipose trans-eQTL and implicate this
trans-expression network in the link between KLF14 variation and risk of metabolic disease.
The trans-regulation uncovers novel biological links between previously-identified genome-
wide significant associations at KLF14 (HDL; T2D), APH1B (HDL) and MRSA (Waist
circumference) and to additional signals where metabolic trait associations have not yet been
established to genome-wide significance (SLC7A10, KLF13, C8orf82, NINJ2). These links
provide a framework for hypothesis-directed investigation of genetic interactions among
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GWAS loci and provide an example of the power of ‘integrative genomics’ to leverage
‘omics data from multiple sources to discover new biological and functional insights.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. KLF14 is a master regulator of gene expression in adipose tissue
p-value distribution of association between the KLF14 cis-eQTL rs4731702 and expression
levels of ~24K probes in adipose tissue.
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Figure 2. Regional signal plots of the KLF14 locus
Left: signal plot of a representative trans -regulated gene in the MuTHER samples (N =
776). Middle: signal plot for the Type 2 Diabetes GWA meta-analysis performed by the
DIAGRAM consortium1 (stage 1 data only, effective sample size 22,044: rs972283 reached
genome-wide significance after further replication). Right: signal plot for the HDL-
cholesterol GWA meta-analysis performed by the Lipid Consortium (N = 99,900)2. Signal
plots of all 10 genome-wide significant trans-regulated genes are included in Supplementary
Figure 2
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